A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback